Lignes directrices de pratique clinique 2008 de l - Canadian ...

ÉFÉrenCes
1. SantéOntario.com. Adresse : http://www.santeontario.com/conditiondetails.aspx?disease_id=163.
Site consulté le 1 er septembre
2008.
2. Hochman JS, McCabe CH, Stone PH, et al, for the TIMI
Investigators. Outcome and profile of women and men presenting
with acute coronary syndromes: a report from TIMI IIIB.
Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997;
30:141-148.
3. Malmberg K, Ryden L. Myocardial infarction in patients with
diabetes mellitus. Eur Heart J. 1988;9:259-264.
4. Bittl JA, Strony J, Brinker JA, et al, for the Hirulog Angioplasty
Study Investigators. Treatment with bivalirudin (Hirulog) as
compared with heparin during coronary angioplasty for unstable
or postinfarction angina. N Engl J Med. 1995;333:764-769.
5. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin
for unstable angina pectoris. A multicenter, randomized angiographic
trial. Circulation. 1994;89:1557-1566.
6. Stone PH, Thompson B, Anderson HV, et al. Influence of race,
sex, and age on management of unstable angina and non-Q-wave
myocardial infarction: the TIMI III registry. JAMA. 1996;275:
1104-1112.
7. Booth GL, Rothwell DM, Fung K, et al. Diabetes and cardiac disease.
In: Hux J, Booth G, Slaughter P, et al. Diabetes in Ontario: An
ICES Practice Atlas. Toronto, ON: Institute for Clinical Evaluative
Sciences; 2003:5.95-5.112.
8. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality for coronary
heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction. N Engl J
Med. 1998;339:229-234.
9. Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence
of diabetes mellitus in patients with myocardial infarction and
effect of diabetes on survival. The Minnesota Heart Survey.
Diabetes Care. 1991;14:537-543.
10. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular
mortality and morbidity: the WHO Mutinational Study of
Vascular Disease in Diabetes. Diabetologia. 2001;44(suppl 2):
S54-S64.
11. Malmberg K, Ryden L, Hamsten A, et al. Mortality prediction in
diabetic patients with myocardial infarction: experiences from
the DIGAMI study. Cardiovasc Res. 1997;34:248-253.
12. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial
infarction case fatality and stroke case fatality in type 2
diabetes: UKPDS 66. Diabetes Care. 2004;27:201-207.
13. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines
for the management of patients with ST elevation myocardial
infarction — executive summary: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Writing Committee to Revise the 1999
Guidelines for the Management of Patients with Acute Myocardial
Infarction). Circulation. 2004;110:588-636.
14. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002
guideline update for the management of patients with unstable
angina and non-ST-segment elevation myocardial infarction—
summary article: a report of the American College of Cardiology/
American Heart Association task force on practice guidelines
(Committee on the Management of Patients with Unstable
Angina). J Am Coll Cardiol. 2002;40:1366-1374.
15. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines
for the management of patients with unstable angina
and non-ST-segment elevation myocardial infarction. A
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on
the Management of Patients with Unstable Angina). J Am Coll
Cardiol. 2000;36:970-1062.
16. Bertrand ME, Simmoons ML, Fox KA, et al. Management of acute
coronary syndromes: acute coronary syndromes without persistent
ST segment elevation. Recommendations of the Task Force
of the European Society of Cardiology. Eur Heart J. 2000;21:
1406-1432.
17. Fibrinolytic Therapy Trialists (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and major
morbidity results from all randomized trials of more than 1000
patients. Lancet. 1994;343:311-322.
18. Grines C, Patel A, Zijlstra F, et al; PCAT Collaborators.
Percutaneous transluminal coronary angioplasty. Primary coronary
angioplasty compared with intravenous thrombolytic therapy
for acute myocardial infarction: six-month follow up and
analysis of individual patient data from randomized trials. Am
Heart J. 2003;145:47-57.
19. Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty
more effective than prehospital fibrinolysis in diabetics with
acute myocardial infarction? Data from the CAPTIM randomized
clinical trial. Eur Heart J. 2005;26:1712-1718.
20. Cannon CP, Weintraub WS, Demopoulos LA et al; TACTICS
(Treat Angina with Aggrastat and Determine Cost of Therapy
with an Invasive or Conservative Strategy) — Thrombolysis in
Myocardial Infarction 18 Invest. Comparison of early invasive
and conservative strategies in patients with unstable coronary
syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
N Engl J Med. 2001;344:1879-1887.
21. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina
to Prevent recurrent Events Trial Investigators. Effects of clopidogrel
in addition to aspirin in patients with acute coronary syndromes
without ST-segment elevation. N Engl J Med. 2001;345:
494-502.
22. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/
IIIa inhibitors reduce mortality in diabetic patients with non-STsegment-elevation
acute coronary syndromes. Circulation. 2001;
104:2767-2771.
23. Mahaffey KW, Granger CB, Toth CA, et al. Diabetic retinopathy
should not be a contraindication to thrombolytic therapy
for acute myocardial infarction: a review of ocular hemorrhage
| S133
CompliCations et troubles Comorbides